Dynavax Technologies (LTS:0IDA) Sale Of Investment : $506.1 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Dynavax Technologies Sale Of Investment?

Dynavax Technologies's sale of investment for the three months ended in Mar. 2024 was $154.3 Mil. It means Dynavax Technologies gained $154.3 Mil from selling investments. Dynavax Technologies's sale of investment for the trailing twelve months (TTM) ended in Mar. 2024 was $506.1 Mil.

Compared with last quarter ($134.4 Mil in Dec. 2023 ), Dynavax Technologies gained more money from selling investments in Mar. 2024 ($154.3 Mil).

Dynavax Technologies Sale Of Investment Historical Data

The historical data trend for Dynavax Technologies's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dynavax Technologies Sale Of Investment Chart

Dynavax Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Sale Of Investment

Get a 7-Day Free Trial

201.81

179.48

187.63

322.45

486.10

Dynavax Technologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Sale Of Investment	Get a 7-Day Free Trial															134.25	99.70	117.78	134.36	154.27

Dynavax Technologies Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $506.1 Mil.

Dynavax Technologies Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Dynavax Technologies's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Dynavax Technologies (LTS:0IDA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (LTS:0IDA) » Definitions » Sale Of Investment

Comparable Companies

Traded in Other Exchanges

DVAX:USA DYF1:Germany

Address

2100 Powell Street, Suite 900, Emeryville, CA, USA, 94608

Website

https://www.dynavax.com

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Dynavax Technologies (LTS:0IDA) Headlines

No Headlines